On Thursday, BioTelemetry BEAT will release its latest earnings report. Here is Benzinga's outlook for the company.
Earnings and Revenue
Based on BioTelemetry management projections, analysts predict EPS of 24 cents per share on revenue of $88.3 million.
BioTelemetry EPS in the same period a year ago totaled 23 cents. Revenue was $53.9 million. The analyst consensus estimate would represent a 4.35 percent increase in the company's earnings. Sales would be up 63.65 percent from the same quarter last year.
BioTelemetry's reported EPS has stacked up against analyst estimates in the past like this:
Quarter | Q3 2017 | Q2 2017 | Q1 2017 | Q4 2016 |
EPS Estimate | 0.26 | 0.21 | 0.16 | 0.18 |
EPS Actual | 0.16 | 0.23 | 0.16 | 0.23 |
Stock Performance
Over the last 52-week period, shares are up 32.46 percent. Given that these returns are generally positive, long-term shareholders can be satisfied going into this earnings release. Over the past 90 days, analysts' have generally adjusted their estimates higher for EPS and revenues.
Analysts have been rating BioTelemetry stock as Neutral. The strength of this rating has risen over the past three months.
Conference Call
Don't be surprised to see the stock move on comments made during its conference call. BioTelemetry's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.